Group 1 - The core viewpoint of the announcement is the successful convening of the second extraordinary general meeting of shareholders in 2025, where all proposed resolutions were approved without any objections [2][4]. - The meeting was held on September 9, 2025, at the company's headquarters in Guangzhou, with all board members and supervisors present [2][3]. - The resolutions included the cancellation of the supervisory board and amendments to the company's articles of association and related rules, all of which were passed [3][4]. Group 2 - The meeting's voting procedures complied with the Company Law and the company's articles of association, ensuring the legitimacy of the proceedings [2][4]. - A total of nine directors and three supervisors attended the meeting, along with the company secretary and all senior executives [3][4]. - The legal firm Beijing Zhonglun Law Firm provided witness services, confirming that the meeting's procedures and voting results were valid and in accordance with relevant laws and regulations [4].

Group 1 - The core point of the article is that Kingmed Diagnostics announced the holding of its second extraordinary general meeting of shareholders in 2025 on September 9, 2025, where several proposals, including the amendment proposal, were approved [2]

证券代码：603882 证券简称：金域医学 公告编号：2025-039 广州金域医学检验集团股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2025 年 9 月 9 日 (二)股东会召开的地点：广州市国际生物岛螺旋三路 10 号金域医学总部大楼 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 611 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 221,099,623 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 47.7270 | (五)公司董事、监事和董事会秘书的出席情况 1、公司在任董事9人，出席9人； 2、公司在任监事 3 人，出席 3 人； 3、董事会秘书汪令来先生出席本次会议；公司全体高管列席本次会议。 二、议案审议情况 (四)表决方式 ...

北京市中伦律师事务所 关于广州金域医学检验集团股份有限公司 2025 年第二次临时股东会的 法律意见书 北京市朝阳区金和东路 20 号院正大中心 3 号南塔 22-31 层 邮编：100020 22-31/F, South Tower of CP Center, 20 Jin He East Avenue, Chaoyang District, Beijing l00020, P.R. China 电话/Tel : +86 10 5957 2288 传真/Fax : +86 10 6568 1022/1838 www.zhonglun.com 北京市中伦律师事务所 关于广州金域医学检验集团股份有限公司 2025 年第二次临时股东会的 二〇二五年九月 法律意见书 致：广州金域医学检验集团股份有限公司 北京市中伦律师事务所（以下简称"本所"）作为广州金域医学检验集团股 份有限公司（以下简称"公司"）的常年法律顾问，受公司委托，指派律师出席 公司 2025 年第二次临时股东会（以下简称"本次股东会"）。本所律师根据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》 ...

Market Overview - The medical services sector increased by 2.28% on September 8, with King Med leading the gains [1] - The Shanghai Composite Index closed at 3826.84, up 0.38%, while the Shenzhen Component Index closed at 12666.84, up 0.61% [1] Top Performers - King Med (603882) closed at 33.31, up 7.94% with a trading volume of 301,000 shares and a transaction value of 99.866 million [1] - Yao Kang Bio (688046) closed at 18.75, up 6.29% with a trading volume of 74,800 shares and a transaction value of 138 million [1] - Digital Human (835670) closed at 19.24, up 5.54% with a trading volume of 101,700 shares and a transaction value of 192 million [1] Underperformers - Hai Te Bio (300683) closed at 41.67, down 2.53% with a trading volume of 86,900 shares and a transaction value of 361 million [2] - Chengda Pharmaceutical (301201) closed at 28.09, down 2.26% with a trading volume of 43,900 shares and a transaction value of 12.2 million [2] - Yi Nuo Si (688710) closed at 39.26, down 1.90% with a trading volume of 13,500 shares and a transaction value of 53.1306 million [2] Capital Flow - The medical services sector saw a net inflow of 115 million from institutional investors, while retail investors experienced a net outflow of 249 million [2][3] - Major stocks like King Med and Wu Yi Kang (603259) attracted significant institutional investment, with net inflows of 91.836 million and 79.3798 million respectively [3]

Investment Rating - The report maintains a "Market Weight" rating for the pharmaceutical and biotechnology industry [6][29]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 1.27% from August 22 to September 4, 2025, which is approximately 3.07 percentage points lower than the index [13][29]. - Most sub-sectors within the industry recorded negative returns during the same period, with the medical research outsourcing and chemical preparation sectors showing the highest gains of 12.17% and 5.45%, respectively. In contrast, the in vitro diagnostics and raw materials sectors experienced declines of 5.96% and 4.95% [16][19]. - Approximately 22% of stocks in the industry recorded positive returns, while around 78% experienced negative returns during the reporting period [17][19]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry was approximately 55.41 times, with a relative PE ratio of 4.23 times compared to the CSI 300 index, indicating little change in industry valuation [20][29]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a decline of 1.27% from August 22 to September 4, 2025 [13]. - Most sub-sectors recorded negative returns, with medical research outsourcing and chemical preparations leading in gains [16]. - About 22% of stocks in the industry had positive returns, while 78% had negative returns [17]. 2. Industry News - The National Healthcare Security Administration announced the list of drugs for the 2025 National Basic Medical Insurance, with 718 submissions and 535 passing the initial review [27]. - The report highlights the upcoming national medical insurance negotiations and the analysis of 25 traditional Chinese medicine products [27]. 3. Company Announcements - Guangzhou Baiyunshan Pharmaceutical Group announced that its subsidiary received approval for a drug to pass the consistency evaluation for generic drugs [28]. 4. Industry Outlook - The report suggests focusing on investment opportunities in the innovative drug sector and related areas, including medical devices and traditional Chinese medicine [29][32].

Core Points - The company is holding its second extraordinary general meeting of shareholders in 2025 on September 9, 2025, at 14:30 [2][3] - The agenda includes four proposals, one of which is to cancel the supervisory board and amend the company's articles of association [7][8] - The meeting will utilize a combination of on-site and online voting methods for shareholders to exercise their voting rights [4][5] Proposal Summaries - **Proposal 1**: The company proposes to cancel the supervisory board and amend the articles of association and related rules to enhance corporate governance [7][8] - **Proposal 2**: The company aims to revise the related party transaction management system to improve governance and operational standards [9][10] - **Proposal 3**: The company intends to amend the external investment management system to align with current regulations and enhance operational efficiency [10][12] - **Proposal 4**: The company seeks to revise the external guarantee management system to ensure compliance with legal and regulatory requirements [12][13] Meeting Procedures - The meeting will be presided over by the chairman, and a secretary will be responsible for the meeting procedures [3][4] - Shareholders wishing to speak must register in advance, and the number of speakers may be limited to ten [6][7] - Voting will be conducted through a written ballot for on-site attendees and an online platform for remote participants [5][6]

广州金域医学检验集团股份有限公司 2025 年第二次临时股东会会议资料 广州金域医学检验集团股份有限公司 2025 年第二次临时股东会 会议资料 二〇二五年九月 广州金域医学检验集团股份有限公司 2025 年第二次临时股东会会议资料 目录 | 广州金域医学检验集团股份有限公司 2025 年第二次临时股东会会议议程 3 | | --- | | 广州金域医学检验集团股份有限公司 2025 年第二次临时股东会会议须知 5 | | 议案一：关于取消公司监事会并修订《公司章程》及相关议事规则的议案 ... 7 | | 议案二：关于修订《广州金域医学检验集团股份有限公司关联交易管理制度》的 | | 议案 9 | | 议案三：关于修订《广州金域医学检验集团股份有限公司对外投资管理制度》的 | | 议案 10 | | 议案四：关于修订《广州金域医学检验集团股份有限公司对外担保管理制度》的 | | 议案 11 | | 附件 1：广州金域医学检验集团股份有限公司章程 12 | | 附件 2：广州金域医学检验集团股份有限公司股东会议事规则 65 | | 附件 3：广州金域医学检验集团股份有限公司董事会议事规则 84 | | 附件 ...

Group 1 - The gene sequencing sector experienced a decline of 3.38%, ranking among the top losers in the concept sector as of the market close on August 27 [2][3] - Within the gene sequencing sector, major companies such as Guangshentang, Ruian Gene, and Puni Testing saw significant declines, while a few companies like Dean Diagnostics, Aiko Optoelectronics, and Kingmed Diagnostics recorded gains of 5.81%, 3.67%, and 2.11% respectively [2][3] - The gene sequencing sector faced a net outflow of 1.543 billion yuan from main funds, with 53 stocks experiencing net outflows, and five stocks seeing outflows exceeding 100 million yuan [3][4] Group 2 - Guangshentang led the outflow with a net withdrawal of 379 million yuan, followed by Anke Bio, Huace Testing, and Yuheng Pharmaceutical with net outflows of 189 million yuan, 118 million yuan, and 116 million yuan respectively [3][4] - On the other hand, the stocks with the highest net inflows included BGI Genomics, Kingmed Diagnostics, and Jiuzhoutong, attracting net inflows of 107 million yuan, 106 million yuan, and 79 million yuan respectively [3][5] - The overall market sentiment in the gene sequencing sector appears to be bearish, as indicated by the significant net outflows and the performance of major stocks within the sector [2][3]

Core Viewpoint - AI-related stocks showed strong performance on August 27, with notable gains in several companies, indicating a positive market sentiment towards the AI sector [1]. Company Performance - Nengke Technology (能科科技) reached a limit-up, marking its second consecutive trading day of gains, with a rise of 10% [2]. - Kute Intelligent (酷特智能) increased by over 8%, reflecting strong investor interest [1]. - Yinkang Life (盈康生命) and Wanxing Technology (万兴科技) also experienced upward movement, contributing to the overall positive trend in AI stocks [1]. - Other companies such as Doushen Education (豆神教育) and Huichan Technology (慧辰股份) also reported gains, with the latter showing a rise of 6.14% [2]. Percentage Changes - Nengke Technology (能科科技) recorded a significant increase of 53.02% in its stock price [2]. - Kute Intelligent (酷特智能) saw a rise of 25.90% [2]. - Yinkang Life (盈康生命) and Wanxing Technology (万兴科技) had increases of 11.27% and 89.88%, respectively [2]. - Doushen Education (豆神教育) experienced a gain of 10.10% [2].